Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

The future of NSCLC: molecular profiles guiding treatment decisions.

Tsao AS, Papadimitrakopoulou VA.

Oncology (Williston Park). 2011 Jun;25(7):607, 614. No abstract available.

2.

ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time.

Socinski MA.

Oncology (Williston Park). 2011 Jun;25(7):601, 604, 607. No abstract available.

3.

Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.

Gadgeel SM.

Lung Cancer. 2017 Jul;109:147-148. doi: 10.1016/j.lungcan.2017.03.008. Epub 2017 Mar 20. No abstract available.

PMID:
28365051
4.

[Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes].

Besse B.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S93-5. doi: 10.1016/S0007-4551(15)31224-8. French.

PMID:
26118884
5.

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.

Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.

Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Review.

PMID:
23472711
6.

Cross-over-it's a feature, not a bug.

Engelsberg A.

Ann Oncol. 2015 Sep;26(9):2000-2. doi: 10.1093/annonc/mdv260. Epub 2015 Jun 15. No abstract available.

7.

Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.

Chuang JC, Neal JW, Niu XM, Wakelee HA.

Lung Cancer. 2015 Oct;90(1):1-7. doi: 10.1016/j.lungcan.2015.07.016. Epub 2015 Jul 30. Review.

PMID:
26275476
8.

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.

Rosell R, Karachaliou N, Wolf J, Ou SH.

Lancet Respir Med. 2014 Dec;2(12):966-8. doi: 10.1016/S2213-2600(14)70259-0. Epub 2014 Nov 19. No abstract available.

PMID:
25466349
9.

[Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer].

Zhang Q, Zhang S.

Zhongguo Fei Ai Za Zhi. 2017 Jan 20;20(1):66-72. doi: 10.3779/j.issn.1009-3419.2017.01.10. Review. Chinese.

10.

Targeted therapy in lung cancer: survival, quality of life improved for some patients.

Printz C.

Cancer. 2014 Sep 1;120(17):2625-6. doi: 10.1002/cncr.28943. No abstract available.

11.

Resensitizing Refractory ALK+ NSCLC: A Case Study.

Poh A.

Cancer Discov. 2016 Mar;6(3):220-1. doi: 10.1158/2159-8290.CD-NB2016-009. Epub 2016 Jan 22. No abstract available.

12.

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.

Eur J Cancer. 2012 May;48(7):961-73. doi: 10.1016/j.ejca.2012.02.001. Epub 2012 Mar 6.

PMID:
22397764
13.

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.

Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F.

Clin Lung Cancer. 2014 May;15(3):173-81. doi: 10.1016/j.cllc.2013.12.002. Epub 2013 Dec 27. Review.

PMID:
24486058
14.

Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.

Saijo N.

Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168. No abstract available.

PMID:
20981125
15.

How should "RET positive" NSCLC be treated?

Smit EF.

Lung Cancer. 2017 Jun;108:250-251. doi: 10.1016/j.lungcan.2017.02.006. Epub 2017 Feb 6. No abstract available.

PMID:
28189265
16.

Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the making.

Passaro A, Barberis M, Catania C, Pessina S, de Marinis F.

Ann Oncol. 2015 Jun;26(6):1270-1. doi: 10.1093/annonc/mdv150. Epub 2015 Mar 19. No abstract available.

PMID:
25791634
17.

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.

Biya J, Caramella C, Lindsay CR, Planchard D, Besse B.

J Thorac Oncol. 2015 Jun;10(6):e44-5. doi: 10.1097/JTO.0000000000000501.

18.

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.

Vijayvergia N, Mehra R.

Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46. doi: 10.1007/s00280-014-2517-6. Epub 2014 Aug 19. Review.

19.

The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer.

Xie J, Zhang X.

J Genet Genomics. 2016 Jan 20;43(1):3-10. doi: 10.1016/j.jgg.2015.09.003. Epub 2015 Sep 15. Review.

20.

[Horizon
--interpretation of ALK-positive non-small cell lung cancer Chinese story].

Liu X.

Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):59-60. doi: 10.3779/j.issn.1009-3419.2015.02.01. Chinese. No abstract available.

Supplemental Content

Support Center